These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 20363190)

  • 1. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    Aggarwal SP; Zinman L; Simpson E; McKinley J; Jackson KE; Pinto H; Kaufman P; Conwit RA; Schoenfeld D; Shefner J; Cudkowicz M;
    Lancet Neurol; 2010 May; 9(5):481-8. PubMed ID: 20363190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
    Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
    Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.
    ; Morrison KE; Dhariwal S; Hornabrook R; Savage L; Burn DJ; Khoo TK; Kelly J; Murphy CL; Al-Chalabi A; Dougherty A; Leigh PN; Wijesekera L; Thornhill M; Ellis CM; O'Hanlon K; Panicker J; Pate L; Ray P; Wyatt L; Young CA; Copeland L; Ealing J; Hamdalla H; Leroi I; Murphy C; O'Keeffe F; Oughton E; Partington L; Paterson P; Rog D; Sathish A; Sexton D; Smith J; Vanek H; Dodds S; Williams TL; Steen IN; Clarke J; Eziefula C; Howard R; Orrell R; Sidle K; Sylvester R; Barrett W; Merritt C; Talbot K; Turner MR; Whatley C; Williams C; Williams J; Cosby C; Hanemann CO; Iman I; Philips C; Timings L; Crawford SE; Hewamadduma C; Hibberd R; Hollinger H; McDermott C; Mils G; Rafiq M; Shaw PJ; Taylor A; Waines E; Walsh T; Addison-Jones R; Birt J; Hare M; Majid T
    Lancet Neurol; 2013 Apr; 12(4):339-45. PubMed ID: 23453347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
    Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
    BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Benatar M; Hansen T; Rom D; Geist MA; Blaettler T; Camu W; Kuzma-Kozakiewicz M; van den Berg LH; Morales RJ; Chio A; Andersen PM; Pradat PF; Lange D; Van Damme P; Mora G; Grudniak M; Elliott M; Petri S; Olney N; Ladha S; Goyal NA; Meyer T; Hanna MG; Quinn C; Genge A; Zinman L; Jabari D; Shoesmith C; Ludolph AC; Neuwirth C; Nations S; Shefner JM; Turner MR; Wuu J; Bennett R; Dang H; Sundgreen C;
    Lancet Neurol; 2024 Jul; 23(7):687-699. PubMed ID: 38782015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial.
    Verstraete E; Veldink JH; Huisman MH; Draak T; Uijtendaal EV; van der Kooi AJ; Schelhaas HJ; de Visser M; van der Tweel I; van den Berg LH
    J Neurol Neurosurg Psychiatry; 2012 May; 83(5):557-64. PubMed ID: 22378918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.
    Dupuis L; Dengler R; Heneka MT; Meyer T; Zierz S; Kassubek J; Fischer W; Steiner F; Lindauer E; Otto M; Dreyhaupt J; Grehl T; Hermann A; Winkler AS; Bogdahn U; Benecke R; Schrank B; Wessig C; Grosskreutz J; Ludolph AC;
    PLoS One; 2012; 7(6):e37885. PubMed ID: 22715372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
    Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
    Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
    Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
    Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
    Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
    Meininger V; Asselain B; Guillet P; Leigh PN; Ludolph A; Lacomblez L; Robberecht W;
    Neurology; 2006 Jan; 66(1):88-92. PubMed ID: 16401852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study.
    Fang T; Al Khleifat A; Meurgey JH; Jones A; Leigh PN; Bensimon G; Al-Chalabi A
    Lancet Neurol; 2018 May; 17(5):416-422. PubMed ID: 29525492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
    Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
    J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.
    Cudkowicz ME; Titus S; Kearney M; Yu H; Sherman A; Schoenfeld D; Hayden D; Shui A; Brooks B; Conwit R; Felsenstein D; Greenblatt DJ; Keroack M; Kissel JT; Miller R; Rosenfeld J; Rothstein JD; Simpson E; Tolkoff-Rubin N; Zinman L; Shefner JM;
    Lancet Neurol; 2014 Nov; 13(11):1083-1091. PubMed ID: 25297012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial.
    Koch JC; Leha A; Bidner H; Cordts I; Dorst J; Günther R; Zeller D; Braun N; Metelmann M; Corcia P; De La Cruz E; Weydt P; Meyer T; Großkreutz J; Soriani MH; Attarian S; Weishaupt JH; Weyen U; Kuttler J; Zurek G; Rogers ML; Feneberg E; Deschauer M; Neuwirth C; Wuu J; Ludolph AC; Schmidt J; Remane Y; Camu W; Friede T; Benatar M; Weber M; Lingor P;
    Lancet Neurol; 2024 Nov; 23(11):1133-1146. PubMed ID: 39424560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
    Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
    Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.
    Dalla Bella E; Bersano E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Filosto M; Giannini F; Spataro R; Lunetta C; Mandrioli J; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Tugnoli V; Verriello L; Volanti P; Furlan R; Nolan JM; Abgueguen E; Tramacere I; Lauria G
    Brain; 2021 Oct; 144(9):2635-2647. PubMed ID: 33905493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.